Skip to content
Screener

Heartflow, Inc. HTFL Cash & Equivalents

Cash & Equivalents at other companies

ITG
Integer HoldingsITGR
$8.12M-74.4%
Boston Scientific logo
Boston ScientificBSX
$850M+146%
Medtronic logo
MedtronicMDT
$1.95B-12.1%
Cytek Biosciences, Inc. logo
Cytek Biosciences, Inc.CTKB
$73.85M-2.2%
Edwards Lifesciences logo
Edwards LifesciencesEW
$2.45B-22.3%
Asset Entities logo
Asset EntitiesASST
$95.09M+982%

Other financials

Income statement

See full
Revenue$52.6M+41.3%
Gross profit$42.2M+50.9%
Operating income-$29.5M-68.6%
Net income-$27.4M+15.4%
EPS (diluted)-$0.32+93.9%

Balance sheet

See full
Total debt$26.3M
Total equity$285.7M+132%
Total assets$344.0M

Cash flow

See full
Operating cash flow-$30.1M-129%
CapEx$1.9M+71.6%
Free cash flow-$32.0M-124%

Valuation

See full
Market cap$2.34B-3.7%
Enterprise value$2.35B
P/S12.3×

Profitability

See full
Gross margin78.1%+2.4pp
Operating margin-39.7%-4.8pp
Net margin-58.4%-12.1pp
FCF margin-40.1%-2.4pp

Returns & leverage

See full
Return on equity37.1%
Debt / equity0.1×
Current ratio5.6×

Where this comes from

Reported directly by Heartflow, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Heartflow, Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:31 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001464521-26-000071
Line itemThree Months Ended / March 31, 2026Three Months Ended / March 31, 2025
Effect of foreign exchange rates262(236)
Net increase (decrease) in cash and cash equivalents(25,112)58,419
Balance, beginning of period49,48555,842
Balance, end of period$24,373$114,261
Supplemental disclosure of cash flow information:
Cash paid for interest$3,439
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable$912$6

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Heartflow, Inc.'s cash & equivalents?
Heartflow, Inc. (HTFL) reported cash & equivalents of $24.37M in Q1 2026.
How has Heartflow, Inc.'s cash & equivalents changed year-over-year?
Heartflow, Inc.'s cash & equivalents decreased by 78.7% year-over-year, from $114.26M to $24.37M.
What is the long-term trend for Heartflow, Inc.'s cash & equivalents?
Over 3 years (2022 to 2025), Heartflow, Inc.'s cash & equivalents has grown at a 6.5% compound annual growth rate (CAGR), from $40.96M to $49.49M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Heartflow, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude